Related Experiment Video
Updated: Jun 12, 2026
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
In vivo assembly of nanoparticle components to improve targeted cancer imaging
Steven D Perrault1, Warren C W Chan
1Institute of Biomaterials and Biomedical Engineering, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, ON, Canada M5S 3E1.
Abstract:
Many small molecular anticancer agents are often ineffective at detecting or treating cancer due to their poor pharmacokinetics. Using nanoparticles as carriers can improve this because their large size reduces clearance and improves retention within tumors, but it also slows their rate of transfer from circulation into the tumor interstitium. Here, we demonstrate an alternative strategy whereby a molecular contrast agent and engineered nanoparticle undergo in vivo molecular assembly within tumors, combining the rapid influx of the smaller and high retention of the larger component. This strategy provided rapid tumor accumulation of a fluorescent contrast agent, 16- and 8-fold faster than fluorescently labeled macromolecule or nanoparticle controls achieved. Diagnostic sensitivity was 3.0 times that of a passively targeting nanoparticle, and this improvement was achieved 3 h after injection. The advantage of the in vivo assembly approach for targeting is rapid accumulation of small molecular agents in tumors, shorter circulation time requirements, possible systemic clearance while maintaining imaging sensitivity in the tumor, and nanoparticle anchors in tumors can be utilized to alter the pharmacokinetics of contrast agents, therapeutics, and other nanoparticles. This study demonstrates molecular assembly of nanoparticles within tumors, and provides a new basis for the future design of nanomaterials for medical applications.
Insights
Researchers developed an in vivo molecular assembly strategy for cancer diagnostics. This approach enhances tumor targeting by combining small molecule contrast agents with nanoparticles for improved detection and retention.
Area of Science:
- Nanomedicine
- Molecular Imaging
- Biotechnology
Background:
- Small molecular anticancer agents often fail due to poor pharmacokinetics, limiting their diagnostic and therapeutic efficacy.
- Nanoparticle drug delivery systems improve tumor retention but face challenges with interstitial transfer.
- Current strategies struggle to balance rapid tumor influx with sustained retention for effective cancer detection.
Purpose of the Study:
- To develop an alternative strategy for improved tumor targeting and diagnostic sensitivity in cancer.
- To combine the rapid tumor accumulation of small molecules with the high retention of nanoparticles.
- To create a novel in vivo molecular assembly approach for enhanced cancer imaging.
Main Methods:
- Engineered nanoparticles and molecular contrast agents were designed for in vivo molecular assembly within tumors.
- The study compared the tumor accumulation rate and diagnostic sensitivity of the in vivo assembly strategy against control groups.
- Fluorescently labeled agents and nanoparticles were utilized to track and quantify accumulation and retention.
Main Results:
- The in vivo assembly strategy achieved 16- and 8-fold faster tumor accumulation of a fluorescent contrast agent compared to controls.
- Diagnostic sensitivity was 3.0 times higher than passively targeting nanoparticles, with significant improvement observed at 3 hours post-injection.
- Demonstrated rapid accumulation of small molecular agents in tumors, reduced circulation time requirements, and maintained imaging sensitivity.
Conclusions:
- In vivo molecular assembly within tumors offers a novel and effective strategy for enhancing cancer diagnostics.
- This approach overcomes limitations of traditional nanoparticle delivery by combining rapid influx and high retention.
- Provides a new foundation for designing advanced nanomaterials for improved medical imaging and therapeutic applications.
